GT Biopharma, Inc. (NASDAQ:GTBP – Get Free Report)’s share price rose 18.5% during trading on Thursday. The company traded as high as $7.40 and last traded at $7.36. 63,035 shares traded hands during trading, an increase of 38% from the average daily volume of 45,536 shares. The stock had previously closed at $6.21.
Wall Street Analyst Weigh In
GTBP has been the topic of several research analyst reports. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of GT Biopharma in a research note on Friday, October 2nd. Wall Street Zen downgraded GT Biopharma to a “strong sell” rating in a research note on Saturday, September 12th. One analyst has rated the stock with a Sell rating. According to MarketBeat, the stock presently has a consensus rating of “Sell”.
Check Out Our Latest Report on GT Biopharma
GT Biopharma Stock Performance
The firm has a market cap of $14.49 million, a P/E ratio of -0.05 and a beta of 0.86. The company’s 50 day moving average is $7.06 and its 200 day moving average is $8.95.
GT Biopharma (NASDAQ:GTBP – Get Free Report) last issued its earnings results on Friday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.04). On average, equities research analysts anticipate that GT Biopharma, Inc. will post -10.75 EPS for the current year.
Hedge Funds Weigh In On GT Biopharma
A hedge fund recently bought a new stake in GT Biopharma stock. 49 Wealth Management LLC bought a new stake in GT Biopharma, Inc. (NASDAQ:GTBP – Free Report) in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 64,000 shares of the company’s stock, valued at approximately $31,000. 49 Wealth Management LLC owned about 0.14% of GT Biopharma at the end of the most recent quarter. 8.15% of the stock is owned by institutional investors and hedge funds.
GT Biopharma Company Profile
GT Biopharma, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on its proprietary TriKE (Tri-specific Killer Engager) platform, which is designed to activate natural killer (NK) cells, direct them toward cancer cells expressing selected tumor antigens, and support NK-cell expansion through an interleukin-15 component.
GT Biopharma’s product candidates are being developed for hematologic malignancies and potentially solid tumors.
Further Reading
- Five stocks we like better than GT Biopharma
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for GT Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GT Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
